Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Top Cited Papers
- 1 September 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 394 (10203), 1030-1040
- https://doi.org/10.1016/s0140-6736(19)31946-4
Abstract
No abstract availableKeywords
Funding Information
- Teva Pharmaceutical Industries
This publication has 31 references indexed in Scilit:
- The International Classification of Headache Disorders, 3rd edition (beta version)Cephalalgia, 2013
- Methodological Issues in Studying Rates and Predictors of Migraine Progression and RemissionHeadache: The Journal of Head and Face Pain, 2013
- Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS‐II)Headache: The Journal of Head and Face Pain, 2013
- Adherence with Migraine Prophylaxis in Clinical PracticePain Practice, 2012
- Defining the Differences Between Episodic Migraine and Chronic MigraineCurrent Pain and Headache Reports, 2011
- CGRP and its receptors provide new insights into migraine pathophysiologyNature Reviews Neurology, 2010
- Migraine prevalence, disease burden, and the need for preventive therapyNeurology, 2007
- Age-dependent prevalence and clinical features of migraineNeurology, 2006
- Topiramate in Migraine PreventionArchives of Neurology, 2004
- Topiramate for Migraine PreventionA Randomized Controlled TrialJAMA, 2004